


10/518317

CERTIFICATE OF MAILING

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Concise Statement of Relevance of Non-English References, Additional Information, Form PTO-1449 (1 Sheets) and 8 references are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date indicated below

Date: 4/4/05

By: *[Signature]*

Attorney Docket No.: 101215-174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--------------|---|---|
| APPLICANT | : | Axel MEYE et al. |
| SERIAL NO. | : | 10/518,317 |
| CUSTOMER NO. | : | 27387 |
| FILED | : | December 14, 2004 |
| FOR | : | Method for Detecting Increased Susceptibility to Tumors |
| ART UNIT | : | TBA |
| EXAMINER | : | TBA |

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

II. Copies of Listed References

Copies of all references listed on the attached Form PTO-1449 are being supplied.

Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

III. Concise Statement of Relevance

All references listed on the attached Form PTO-1449 are in the English language, and, therefore, a concise statement of relevance is not required.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By



Bruce S. Londa
Reg. No. 33,531
875 Third Avenue
18th Floor
New York, New York 10022
(212) 808-0700

| | | | | | | | |
|--|----|---|-------------|--------------------------------|-------------------------|------------------------|--------------------------------------|
| LIST OF PATENTS AND PUBLICATIONS APPLICANT'S INFORMATION APR 06 2005 CLOSURE STATEMENT (Form PTO-1449) | | | | Attorney Docket: 101215-174 | | Serial No.: 10/518,317 | |
| | | | | Applicant: Axel MEYE et al. | | Examiner: TBA | |
| | | | | Filing Date: December 14, 2004 | | Group: TBA | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner's Initial | | Document Number | Date | Name | Class | Sub Class | Filing Date If appropriate |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Date | Country | Class | Sub Class | Translation Yes No |
| | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AA | Freedman, D.A. et al.; "Functions of the MDM2 Oncoprotein"; 1999, Cell Mol Life Sci 55: 96-107 | | | | | |
| | AB | Juven-Gershon, T. et al.; "Mdm2: The Ups and Downs"; 1999, Mol Med 5: 71-83 | | | | | |
| | AC | Momand, J. et al.; "MDM2 -- Master Regulator of the p53 Tumor Suppressor Protein"; 2000, Gene 242: 15-29 | | | | | |
| | AD | Würl, Peter et al.; "Prognostic Relevance of C-Terminal Mdm2 Detection is Enhanced by p53 Positivity in Soft Tissue Sarcomas"; 1997, Diagnostic Molecular Pathology 6(5): 249-254 | | | | | |
| | AE | Taubert, Helge et al.; "A MboII Polymorphism in Exon 11 of the Human <i>MDM2</i> Gene Occuring in Normal Blood Donors and in Soft Tissue Sarcoma Patients: An Indication for an Increased Cancer Susceptibility?"; 2000, Mutation Research 456: 39-44 | | | | | |
| | AF | Schlott, Thilo et al.; "Point Mutations and Nucleotide Insertions in the <i>MDM2</i> Zinc Finger Structure of Human Tumours"; 1997, Journal of Pathology, Vol. 182, pp. 540-61. | | | | | |
| | AG | Heighway, Jim et al.; "A Transcribed Polymorphism and Sub0-Localisation of MDM2"; May 1994, Human Genetics, 93(5): 611-612 | | | | | |
| | AH | Silva, Javier et al.; "Absence of Point Mutations at Codon 17 of the Mdm2 Gene (Serine 17) in Human Primary Tumors"; 2000, Mutation Research, 449: 41-45 | | | | | |
| EXAMINER: | | | | | DATE CONSIDERED: | | |
| • EXAMINER: Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant. | | | | | | | |